Figure 3

Ang II-derived synthetic peptides reduced parasitemia and Ang II-SS increased survival in experimental cerebral malaria and severe non-cerebral malaria mouse models. C57BL/6 (cerebral malaria model) and BALB/c (non-cerebral malaria model) mice received a single daily dose (100 ng Kg⁻¹ min⁻¹) of Ang II (brown line), Ang II-SS (orange line), VIPF (blue line), or vehicle (PBS, black line) for 5 days. The initial dose was injected one hour before mice were infected with P. berghei ANKA. Parasitemia was monitored by Diff-Quick stained blood smears from day 3 to day 7 for C57BL/6 mice (A) and from day 3 to day 9 for BALB/c mice (B). Percentage of survival for C57BL/6 mice (C) and BALB/c mice (D) mice was monitored daily starting on day 6 p.i. Data in A and B are shown as mean ± SD from a single experiment. *P < 0.05, **P < 0.01, ***P < 0.001, as determined by two-way ANOVA followed by Tukey’s multiple comparisons test compared to vehicle (black asterisks) or Ang II-SS (orange asterisks), n = 8. Data in C and D are shown as Kaplan–Meier plots of the percentage of surviving mice. Treated groups were compared to the vehicle group by log rank (Mantel-Cox) test, n = 8.